Get the Stockscreener App
3.38
2.59%
-0.09
Galectin Therapeutics Inc stock is traded at $3.38, with a volume of 302.93K.
It is down -2.59% in the last 24 hours and down -32.26% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$3.47
Open:
$3.5
24h Volume:
302.93K
Relative Volume:
0.49
Market Cap:
$222.60M
Revenue:
-
Net Income/Loss:
$-26.25M
P/E Ratio:
-8.2459
EPS:
-0.4099
Net Cash Flow:
$-20.05M
1W Performance:
-15.50%
1M Performance:
-32.26%
6M Performance:
+7.30%
1Y Performance:
+16.15%
1-Day Range:
$3.32
$3.5842
1-Week Range:
$3.32
$4.1499
52-Week Range:
$2.025
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
3.38 | 222.60M | 0 | -26.25M | -20.05M | -0.4099 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 37.17B | 4.29B | 577.22M | 641.34M | 4.2086 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics Inc (GALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galectin Therapeutics Inc (GALT) Cash Flow - TradingKey
Galectin Therapeutics Inc (GALT) Institutional Confidence - TradingKey
GALT|Galectin Therapeutics Inc|Price:3.470|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
GALT|Galectin Therapeutics Inc|Price:3.390|Chg%:-0.080 - TradingKey
Galectin Therapeutics (NASDAQ:GALT) Breaks a Key Trend Line - Kalkine Media
GALT stock reacts to Galectin Therapeutics Q1 2026 cash position and R&D progress - Ad-hoc-news.de
Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics Inc (GALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GALT stock gains support as Galectin Therapeutics keeps cash focus - Ad-hoc-news.de
Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock - Investing.com
Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan - Stock Titan
Galectin Therapeutics CMO Jamil Khurram disposes of 16,250 common shares for $83,284.5 - Bitget
Can Galectin Therapeutics (NASDAQ:GALT) Regain Confidence? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research - MarketBeat
Price to book forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
$Galectin Therapeutics (GALT.US)$ - Moomoo
$Galectin Therapeutics (GALT.US)$ put CMO at the table with who at solar? - Moomoo
GALT jumps 11% on FDA alignment for belapectin phase III path in MASH - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Enterprise value to revenue forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Price to sales forward of Galectin Therapeutics Inc. – NASDAQ:GALT - TradingView
Galectin Therapeutics (GALT) Gains 4.16% as Biotech Momentum BuildsTriple Top - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Form 4 Galectin Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock - Investing.com
Galectin Therapeutics CMO Jamil Khurram disposes of $262,083 in stock By Investing.com - Investing.com Nigeria
Galectin Therapeutics director sells $150,890 in common stock By Investing.com - Investing.com South Africa
[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity - Stock Titan
Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale - Stock Titan
Top 3 Health Care Stocks That May Keep You Up At Night In June - Benzinga
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Harold Shlevin files Form 144: GALT (NASDAQ) sale of 7,732 shares - Stock Titan
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2500 Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Index - marketscreener.com
Galectin Therapeutics (GALT) Slips 1.8% as Stock Tests Key Support at $4.66Volume Oscillator - dars.gov.et
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 2000 Value Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000E Growth Benchmark - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM:GALT) added to Russell Small Cap Completeness Index - marketscreener.com
Galectin Therapeutics Inc.(NasdaqCM: GALT) added to Russell 3000 Growth Benchmark - marketscreener.com
If you're not following me on stocktwits you probably should My money is on a partnership with Madrigal - Moomoo
GALT stock surges 22% — on track for best day in over a year after FDA clears path for late-stage belapectin trial - MSN
Form 144 GALECTIN THERAPEUTICS INC For: 26 June - Investing.com UK
Form 144 GALECTIN THERAPEUTICS INC For: 26 June By Investing.com - Investing.com Nigeria
GALT (NASDAQ: GALT) Rule 144 notice: Khurram Jamil reports share disposals - Stock Titan
Form 144 GALECTIN THERAPEUTICS INCORPORATED For: 26 June By Investing.com - Investing.com Canada
[144] GALECTIN THERAPEUTICS INC SEC Filing - Stock Titan
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):